Clinical Report: Evaluating Treatment Options for Opioid Use Disorder

Background

Opioid use disorder (OUD) remains a significant public health challenge, with individuals experiencing nonfatal overdoses at increased risk for subsequent fatal overdoses. Opioid agonist therapy (OAT) with buprenorphine-naloxone or methadone has been shown to reduce mortality and overdose risk, making the comparative effectiveness of these treatments critical for patient outcomes (Kleinman et al, 2023).

Data Highlights

In a cohort study, 40% of eligible individuals were excluded after propensity score matching. The median retention for methadone was 25 days, while for buprenorphine-naloxone, it was 16 days. Approximately 6% of participants died within one year, and nearly 90% stopped treatment during follow-up.

Key Findings

• Individuals with OUD who experience a nonfatal overdose have a higher risk of subsequent fatal overdose.

• Initiation of methadone after an overdose was associated with a survival benefit compared to buprenorphine-naloxone.

• Buprenorphine-naloxone was linked to lower overdose risk during treatment (HR for methadone vs buprenorphine-naloxone, 1.52; 95% CI, 1.19-1.93).

• Retention rates for methadone and buprenorphine-naloxone were low, with median retention of only 25 days and 16 days, respectively.

• Approximately 6% of participants died within one year, and nearly 90% stopped treatment during follow-up.

• Generalizability of the findings may be limited due to exclusion of 40% of eligible individuals after propensity score matching.

Clinical Implications

Clinicians should be aware of the differing treatment histories and potential risks associated with methadone and buprenorphine-naloxone. The findings suggest a need for improved access to OAT and innovative strategies to enhance patient retention in treatment.

Conclusion

The study underscores the importance of ongoing research to validate treatment outcomes for OUD and the need for a focus on patient engagement in care.

Related Resources & Content

1. Kleinman et al, Canadian cohort study, 2023 -- Evaluating Treatment Options for Opioid Use Disorder

2. SAMHSA, Treatment Options for Substance Use Disorder, 2024 -- Guidelines and policy landscape

3. JAMA Network Open, Comparative Effectiveness of Methadone and Buprenorphine-Naloxone, 2024 -- Study findings

4. Drugs - Real World Outcomes — An Extensive Observational Analysis of Trends and Risk Factors Associated with Opioid Overdose: Insights from Real-World Data for Improved Opioid Prescribing

5. JAMA Network Open — Cost-Effectiveness of the START Hospital Addiction Consultation Service for Opioid Use Disorder Treatment

6. JAMA Network Open — Adjunctive Psychosocial Interventions and Opioid Abstinence Among Patients Receiving Buprenorphine: A

7. Treatment Options for Substance Use Disorder | SAMHSA

8. Comparative Effectiveness of Methadone and Buprenorphine-Naloxone

9. Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder | Substance Use and Addiction Medicine | JAMA | JAMA Network

10. Receipt of addiction treatment after nonfatal opioid overdose and risk of subsequent overdose: a retrospective cohort study - PMC